We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

130 hedge funds and large institutions have $2.77B invested in MoonLake Immunotherapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 52 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more capital invested

Capital invested by funds: $2.34B → $2.77B (+$434M)

5% more call options, than puts

Call options by funds: $39.6M | Put options by funds: $37.7M

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

2.06% less ownership

Funds ownership: 94.65% → 92.59% (-2.1%)

4% less funds holding

Funds holding: 136 → 130 (-6)

15% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 27

29% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 52

Holders
130
Holders Change
-6
Holders Change %
-4.41%
% of All Funds
1.71%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
23
Increased
37
Reduced
52
Closed
27
Calls
$39.6M
Puts
$37.7M
Net Calls
+$1.9M
Net Calls Change
-$10.4M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$56.2M
2
RI
RTW Investments
New York
+$30.2M
3
SL
Siren LLC
Connecticut
+$20.7M
4
VPC
Vestal Point Capital
New York
+$14.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$14M

Top Sellers

Rank Fund Capital Flow
1
PCH
Polar Capital Holdings
United Kingdom
-$34.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$24.3M
3
CCM
Camber Capital Management
Massachusetts
-$17.2M
4
FC
Finepoint Capital
Massachusetts
-$17M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$14.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
RAM
126
Riggs Asset Management
Pennsylvania
$1.13K +$978 +24 New
IA
127
IFP Advisors
Florida
$802 +$693 +17 New
S
128
SignatureFD
Georgia
$519 +$448 +11 New
PS
129
Principal Securities
Iowa
$378 +$326 +8 New
TWD
130
True Wealth Design
Ohio
$236 +$41 +1 +25%
CCM
131
Camber Capital Management
Massachusetts
– -$17.2M -441,000 Closed
FC
132
Finepoint Capital
Massachusetts
– -$17M -435,785 Closed
Millennium Management
133
Millennium Management
New York
– -$13.5M -344,320 Closed
Franklin Resources
134
Franklin Resources
California
– -$7.48M -191,500 Closed
Holocene Advisors
135
Holocene Advisors
New York
– -$7.38M -188,989 Closed
FTM
136
First Turn Management
California
– -$7M -179,196 Closed
NIP
137
Nicholas Investment Partners
California
– -$1.83M -46,933 Closed
Two Sigma Investments
138
Two Sigma Investments
New York
– -$1.39M -35,638 Closed
Jane Street
139
Jane Street
New York
– -$1.12M -27,489 Closed
Walleye Capital
140
Walleye Capital
New York
– -$1.05M -26,764 Closed
Two Sigma Advisers
141
Two Sigma Advisers
New York
– -$992K -25,400 Closed
CF
142
Cantor Fitzgerald
New York
– -$977K -25,000 Closed
WC
143
Wexford Capital
Florida
– -$840K -21,500 Closed
JGC
144
J. Goldman & Co
New York
– -$597K -14,664 Closed
BC
145
BIT Capital
Germany
– -$571K -14,610 Closed
SSA
146
Schonfeld Strategic Advisors
New York
– -$417K -10,669 Closed
Allianz Asset Management
147
Allianz Asset Management
Germany
– -$387K -9,900 Closed
DFCM
148
Dark Forest Capital Management
Puerto Rico
– -$372K -9,510 Closed
CAU
149
Caxton Associates (UK)
– -$347K -8,880 Closed
XT
150
XTX Topco
Cayman Islands
– -$332K -8,495 Closed
3 4 5
6
7

MLTX Hedge Fund Activity: Q2 2025 in Review

130 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2025, worth a combined $2.77B — up 19% from $2.34B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of MLTX and 23 opened new positions — a net loss of 4 holders — while 52 trimmed existing stakes and 37 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $56.2M. The largest seller was Polar Capital Holdings, cutting an estimated $34.7M.

  • 130 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2025, down from 136 in Q1 2025.
  • Funds reported $2.77B of MoonLake Immunotherapeutics stock for Q2 2025, up 19% quarter-over-quarter.
  • 23 funds opened new MoonLake Immunotherapeutics positions in Q2 2025 and 27 closed out, a net change of -4 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2025 was Avoro Capital Advisors, an estimated $56.2M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2025 was Polar Capital Holdings, an estimated $34.7M sold.

Based on aggregated 13F filings for Q2 2025.